39 abstracts found.



Results filter

Scheduling nab-paclItaxEl combined with GEmcitabine as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC) in the SIEGE randomised trial: a test of bench to bedside concept.

Year:

Session type:

Pippa Corrie1,Wendi Qian1,Aarthi Gopinathan2,Juan W. Valle3,Bristi Basu4,Stephen Falk5,Chinenye Iwuji6,Harpreet Wasan7,Daniel Palmer8,Martin Scott-Brown9,Jonathan Wadsley10,Seema Arif11,John Bridgewater12,David Propper13,Roopinder Gillmore14,Michael Williams2,Rebecca Brais1,Katy Dalchau1,Lisa Bax1,Purity Bundi1,Richard Skells1,Andrea Machin1,Albrecht Neesse15,David Tuveson16,Duncan Jodrell1
1Cambridge University Hospitals NHS Foundation Trust,2Cancer Research UK - Cambridge Institute,3The Christie Hospital NHS Foundation Trust,4Cambridge University Hospital NHS Foundation Trust,5Bristol Haematology and Oncology Centre,6Leicester Royal Infirmary,7Hammersmith Hospital - Imperial College Healthcare NHS Trust,8Clatterbridge Cancer Centre NHS Foundation Trust,9,10Weston Park Hospital - Sheffield,11Velindre Cancer Centre - Cardiff,12University College London Hospitals NHS Foundation Trust,13Barts Health NHS Trust,14The Royal Free Hospital - London,15Universitätsmedizin Göttingen - Vorstand,16Cold Spring Harbor Laboratory - NY

Final DFS results of the SCOT study: An international Phase III Randomised (1:1) Non-inferiority Trial Comparing 3 months vs 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer

Year:

Session type:

Timothy Iveson1,Rachel S Kerr2,Mark P Saunders3,Jim Cassidy4,Niels Henrik Hollander5,Josep Tabernero6,Andrew Haydon7,Bengt Glimelius8,Andrea Harkin4,Karen Allan4,John McQueen4,Claire Scudder9,Kathleen Anne Boyd10,Andrew Briggs10,David Propper11,John Bridgewater12,Ashraf Azzabi13,David Farrugia14,Andrew Webb15,David Cunningham16,Tamas Hickish17,Andrew Weaver18,Simon Gollins19,Harpreet S Wasan20,James Paul4
1University Hospital Southampton,2University of Oxford, Department of Oncology, Oxford,3The Christie Hospital, Manchester,4Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow,5Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5, DK 4700, Naestved,6Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona,7Australasian Gastro-Intestinal Trials Group (AGITG),8University of Uppsala,9OCTO, University of Oxford, Department of Oncology, Oxford,10Institute of Health and Wellbeing, University of Glasgow, Glasgow,11Barts Cancer Institute, Queen Mary, University of London, London,12University College London, London,13Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle,14Gloucestershire Oncology Centre, Cheltenham General Hospital,15Brighton and Sussex University Hospital Trust, Brighton,16Royal Marsden, London UK (funded by NIHR BRC at the Royal Marsden),17Poole Hospital/Bournemouth University, Bournemouth,18Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford,19North Wales Cancer Treatment Centre, Rhyl,20Hammersmith Hospital, Imperial College London, London

Combined analysis of the FOXFIRE prospective randomised studies of first-line selective internal radiotherapy in patients with liver metastases from colorectal cancer

Year:

Session type:

Ricky Sharma1,Peter Gibbs2,E. Anne Francis3,Sarah Pearson4,Sharon Love5,Joanna Moschandreas5,Peter Dutton5,Pradeep S. Virdee5,Val Lewington6,Greg Wilson7,Paul Tait8,Nas Khan9,Dave Berry10,Andy Wotherspoon11,Bruno Morgan12,Ian Chau13,Amir Montazeri14,Daniel Swinson15,Ewan Brown16,Sarah Lowndes17,Paul Ross18,Joanne Hornbuckle19,Alastair Gray20,Guy van Hazel21,Harpreet Wasan22,FOXFIRE, SIRFLOX and FOXFIRE-Global trial investigators FOXFIRE, SIRFLOX and FOXFIRE-Global trial investigators23
1University College London,2Western Hospital, Footscray, Victoria,3Oncology Clincal Trials Office, Department of Oncology, University of Oxford,4Oncology Clinical Trials Office, Department of Oncology, University of Oxford,5Centre for Statistics in Medicine, University of Oxford,6Nuclear Medicine Department, Guy's Hospital, King's College London,7The Christie NHS Foundation Trust,8Imperial College London,9Royal Marsden and Chelsea & Westminster Hospital,10University Hospital Southampton,11The Royal Marsden NHS Foundation Trust,12University of Leicester,13Royal Marsden Hospital, London and Surrey,14The Clatterbridge Cancer Centre NHS foundation Trust, Wirral,15Leeds Teaching Hospital NHS Trust,16Edinburgh Cancer Centre, Western General Hospital, Edinburgh,17Great Western Hospitals NHS Foundation Trust Great Western Hospital, Swindon,18Guy's & St Thomas' NHS Foundation Trust, London,19Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield,20Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford,21University of Western Australia, Perth,22Imperial College Healthcare NHS Trust & Imperial College,23University of Oxford

Perioperative chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: mature analysis of overall survival in the New EPOC randomised controlled trial

Year:

Session type:

John Bridgewater1,Siân Pugh2,Amy Whitehead3,Louise Stanton3,Zina Eminton3,Jane Mellor3,Alex Allen3,Meg Finch-Jones4,Stephen Falk4,Tim Iveson5,Myrddin Rees6,Juan Valle7,Jo Hornbuckle8,Tamas Hickish9,David Cunningham10,Tim Maughan11,O James Garden12,Gareth Griffiths3,John Primrose2,New EPOC Investigators3
1University College London,2University of Southampton,3Southampton Clinical Trials Unit,4University Hospitals Bristol NHS Foundation Trust,5University Hospital Southampton NHS Foundation Trust,6Hampshire Hospitals NHS Foundation Trust,7The Christie NHS Foundation Trust,8Sheffield Teaching Hospitals NHS Foundation Trust,9Poole Hospital and Bournemouth University,10The Royal Marsden Hospital NHS Foundation Trust,11CRUK/MRC Oxford Institute for Radiation Oncology,12The University of Edinburgh

Results of the OPARATIC trial: a phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM)

Year:

Session type:

Anthony Chalmers1,Garth Cruickshank2,Laurence Dunn3,Sara Erridge4,Lisa Godfrey5,Christopher Herbert6,Sarah Jefferies7,Juanita Lopez8,Catherine McBain9,Marc Pittman5,Rebecca Sleigh10,Colin Watts11,Mark Webster-Smith5,Sarah Halford5
1Glasgow Centre for Cancer Research,2University of Birmingham,3University of Glasgow,4University of Edinburgh,5Cancer Research UK,6University Hospitals Bristol NHS Foundation Trust,7Cambridge University Hospitals NHS Trust,8Institute of Cancer Research,9The Christie NHS Foundation Trust,10LGC,11University of Cambridge

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial

Year:

Session type:

Philippa Corrie1,Andrea Marshall2,Paul Nathan3,Paul Lorigan4,Martin Gore5,Saad Tahir6,Guy Faust7,Charles Kelly8,Maria Marples9,Sarah Danson10,Ernest Marshall11,Stephen Houston12,Ruth Board13,Ashita Waterston14,Jenny Nobes15,Mark Harries16,Satish Kumar17,Gemma Young1,Emily Barker1,Janet Dunn18,Mark Middleton19
1Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge,2Warwick Clinical Trials Unit, University of Warwick, Coventry,3Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex,4University of Manchester and Christie NHS Foundation Trust, Manchester,5Royal Marsden Hospital NHS Trust, London,6Oncology Research, Broomfield Hospital, Chelmsford,7Oncology Department, Leicester Royal Infirmary, Leicester,8Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle upon Tyne,9St James’s Institute of Oncology, St James’s University Hospital, Leeds,10Academic Unit of Clinical Oncology, Sheffield Experimental Cancer Medicine Centre, University of Sheffield, Weston Park Hospital, Sheffield,11Cancer & Palliative Care, St. Helen’s Hospital, St. Helens,12Oncology Department, Royal Surrey County Hospital, Surrey,13Rosemere Cancer Centre, Royal Preston Hospital, Preston,14Clinical Trials Unit, Beatson WOS Cancer Centre, Glasgow,15Dept of Clinical Oncology, Norfolk & Norwich University Hospital, Norwich,16Guy’s & St. Thomas’ Hospital, London,17Velindre Cancer Centre, Cardiff,18University of Warwick,19Oxford NIHR Biomedical Research Centre, Oxford

The NCRI Myeloma XI study: a large adaptive randomised clinical trial successfully answering a diverse range of key questions in multiple myeloma.

Year:

Session type:

Walter Gregory1,Graham Jackson2,Charlotte Pawlyn3,David Cairns1,Alina Striha1,Anna Waterhouse1,John Jones3,Bhuvan Kishore4,Mamta Garg5,Cathy Williams6,Kamaraj Karunanithi7,Jindriska Lindsay8,Matthew Jenner9,Gordon Cook1,Martin Kaiser3,Mark Drayson10,Roger Owen11,Nigel Russell12,Faith Davies13,Gareth Morgan14
1University of Leeds,2University of Newcastle,3The Institute of Cancer Research, London,4Department of Haematology and Stem Cell Transplantation, Heart of England NHS Foundation Trust, Birmingham,5Leicester Royal Infirmary,6Nottingham University Hospital,7University Hospital of North Midlands, Stoke-on-Trent,8East Kent Hospitals University NHS Foundation Trust,9University Hospital Southampton NHS Foundation Trust,10University of Birmingham,11Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds,12Department of Haematology, Nottingham University Hospitals NHS Trust,13,14Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR

Adjuvant capecitabine for biliary tract cancer (BTC): The UK BILCAP randomized study

Year:

Session type:

John Bridgewater1,Richard Fox2,Daniel Palmer3,Raj Prasad4,Darius Mirza5,Alan Anthoney6,Pippa Corrie7,Stephen Falk8,Harpreet Wasan9,Paul Ross10,Lucy Wall11,Jonathan Wadsley12,Jeff Evans13,Deborah Stocken2,Raaj Praseedom7,David Cunningham14,James Garden15,Clive Stubbs2,Juan Valle16,John Primrose17
1UCL,2Cancer Research UK Clinical Trials Unit, University of Birmingham,3University of Liverpool,4University of Leeds,5QE Hospital & Birmingham Children's Hospital,6Leeds Teaching Hospitals NHS Trust,7Addenbrooke's Hospital NHS Trust,8University Hospitals Bristol,9Imperial Healthcare NHS Trust,10Guys and St Thomas’ NHS Trust,11Lothian NHS Trust,12jonathan.wadsley@sth.nhs.uk,13Beatson Institute,14Royal Marsden NHS Trust,15University of Edinburgh,16The Christie,17University of Southampton

Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE(NCT00268476)

Year:

Session type:

Theme:

Nicholas D James1,13,Matthew R Sydes2,Malcolm D Mason3,Noel W Clarke14,David P Dearnaley4,Melissa R Spears2,Robin Millman15,Christopher C Parker8,Alastair W S Ritchie2,J Martin Russell5,John Staffurth11,Robert J Jones5,Shaun P Tolan6,John Wagstaff7,Andrew Protheroe8,Rajaguru Srinivasan9,Alison J Birtle10,Joe M O’Sullivan11,Richard Cathomas12,Mahesh K B Parmar2

1University of Warwick, Coventry, UK,2MRC Clinical Trials Unit at UCL, London, UK,3Velindre Hospital, Cardiff, UK,4The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK,5Beatson West of Scotland Cancer Centre, Glasgow, UK,6Clatterbridge Cancer Centre, Wirral, UK,7South West Wales Cancer Institute, Swansea, UK,8University of Oxford Medical Oncology Department, Oxford, UK,9Royal Devon and Exeter NHS Foundation Trust, Exeter, UK,10Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK,11Belfast City Hospital, Belfast, UK,12Kantonsspital Chur, Chur, Switzerland,13Queen Elizabeth Hospital, Birmingham, UK,14The Christie and Salford Royal Hospitals, Manchester, UK,15Prostate Cancer Support Group, Middlesbrough, UK


CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy treatment-naïve patients (pts) with advanced melanoma (MEL)

Year:

Session type:

Theme:

Jedd Wolchok1,Vanna Chiarion-Sileni2,Rene Gonzalez3,Piotr Rutkowski4,Jean Grob5,Charles Cowey6,Christopher Lao7,Dirk Schadendorf8,Pier Ferrucci9,Michael Smylie10,Reinhard Dummer11,Andrew Hill12,John Haanen13,Michele Maio14,Grant McArthur15,Arvin Yang16,Linda Rollin17,Christine Horak16,James Larkin18,Stephen Hodi19

1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA,2Oncology Institute of Veneto IRCCS, Padua, Italy,3University of Colorado Cancer Center, Denver, CO, USA,4Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland,5Hospital de la Timone, Marseille, France,6Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA,7University of Michigan, Ann Arbor, MI, USA,8Department of Dermatology, University of Essen, Essen, Germany,9European Institute of Oncology, Milan, Italy,10Cross Cancer Institute, Edmonton, AB, Canada,11Universitäts Spital, Zurich, Switzerland,12Tasman Oncology Research, Queensland, Australia,13Netherlands Cancer Institute, Amsterdam, The Netherlands,14Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy,15Peter MacCallum Cancer Centre, Victoria, Australia,16Bristol-Myers Squibb, Princeton, NJ, USA,17Bristol-Myers Squibb, Wallingford, CT, USA,18Royal Marsden Hospital, London, UK,19Dana-Farber Cancer Institute, Boston, MA, USA


Page 1 of 41...Last »